17.06.2010 • News

Symyx Shares Fall after Ending Talks with Possible Buyer

Shares of Symyx Technologies fell 14% Wednesday, a day after the company said it ended talks with Certara, which revoked its offer to buy the scientific research provider for $6.75 a share.

Earlier this month, Symyx agreed to provide information about itself and help Certara, the parent of certain scientific software makers, and its private equity sponsor Vector Capital, with the due diligence process.

Before it received Certara's offer, the company had agreed to merge with Accelrys Inc in a stock deal, which valued Symyx at a little more than $5 a share, or about $175 million. After the merger, each company would own about 50% of the combined entity.

In a regulatory filing on Tuesday, Symyx posted Certara's letter, which said it could offer a substantial cash premium over Accelrys' offer, but not $6.75 a share.

Symyx said it does not have a superior offer under consideration.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.